Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$101.88 USD

101.88
10,180,742

-0.44 (-0.43%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

Zacks.com users have recently been watching Merck & Co. (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair

Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.

AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio

AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?

Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.

Merck (MRK) Gains As Market Dips: What You Should Know

Merck (MRK) closed at $123.85 in the latest trading session, marking a +0.19% move from the prior day.

Kinjel Shah headshot

Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates

AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.

Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study

Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.

The Zacks Analyst Blog Highlights JPMorgan Chase, Merck, SAP, Lam Research and Brown-Forman

JPMorgan Chase, Merck, SAP, Lam Research and Brown-Forman are included in this Analyst Blog.

Merck (MRK) Laps the Stock Market: Here's Why

Merck (MRK) concluded the recent trading session at $123.85, signifying a +1.35% move from its prior day's close.

Sheraz Mian headshot

Top Research Reports for JPMorgan Chase, Merck & SAP

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Merck & Co., Inc. (MRK) and SAP SE (SAP).

AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B

AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.

Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know

Merck (MRK) concluded the recent trading session at $120.51, signifying a -1.35% move from its prior day's close.

Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab

Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.

Here's Why Merck (MRK) Fell More Than Broader Market

Merck (MRK) concluded the recent trading session at $122.16, signifying a -0.41% move from its prior day's close.

Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is Vident U.S. Equity Strategy ETF (VUSE) a Strong ETF Right Now?

Smart Beta ETF report for VUSE

Why Moderna (MRNA) Stock Price Was Up 9% on Monday

Moderna (MRNA) surges amid initiation reports of a phase II/III study on Merck-partnered experimental cancer therapy to treat patients with cutaneous squamous cell carcinoma, a form of skin cancer.

J&J (JNJ) Seeks Expanded Use of Tremfya for Ulcerative Colitis

Tremfya is an important drug in J&J's (JNJ) immunology drugs portfolio and a key driver of top-line growth.

Here's Why Merck (MRK) Gained But Lagged the Market Today

Merck (MRK) reachead $123.99 at the closing of the latest trading day, reflecting a +0.19% change compared to its last close.

Gilead (GILD) & MRK's HIV Oral Combo Shows Efficacy in Phase II

Gilead (GILD) and Merck's (MRK) phase II study data demonstrates the efficacy of their oral once-weekly combination of islatravir and lenacapavir in maintaining viral suppression in individuals with HIV.

Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know

In the most recent trading session, Merck (MRK) closed at $126.96, indicating a -0.15% shift from the previous trading day.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK

The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively

Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges

Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.